Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View

Eli Lilly and Company (LLY) reported second-quarter 2024 adjusted earnings per share (“EPS”) of $3.92, which comprehensively beat the Zacks Consensus Estimate of $2.64 per share. Earnings rose 86% year over year.Revenues of $11.3 billion rose 36% year over year. Total revenues beat the Zacks Consensus Estimate of $9.83 billion.Higher volumes of drugs like Mounjaro, Zepbound, Verzenio and Taltz made up for a difficult comparison with the year-ago quarter, which included revenues from the sale of Baqsimi righ ...